Back to top
more

Emergent Biosolutions (EBS)

(Real Time Quote from BATS)

$14.19 USD

14.19
961,268

+0.38 (2.75%)

Updated Jul 25, 2024 10:36 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Emergent Biosolutions (EBS) Q1 Earnings Lag Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -25% and 3.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for April 28th

by Zacks Equity Research

LAZR, EBS, and ROCK have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2022

Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More

by Zacks Equity Research

Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.

Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 12.68% and 6.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Emergent (EBS) Begins Dosing in Phase I Cyanide Poisoning Study

by Zacks Equity Research

Emergent (EBS) initiates dosing in a phase I study evaluating stabilized isoamyl nitrite, the company's investigational single-use intranasal spray for treating acute cyanide poisoning.

New Strong Sell Stocks for March 11th

by Zacks Equity Research

AVVIY, EBS, and NVEI have been added to the Zacks Rank #5 (Strong Sell) List on March 11, 2022.

Emergent's (EBS) Q4 Earnings & Sales Beat, CDMO View Cut

by Zacks Equity Research

Emergent's (EBS) fourth-quarter 2021 earnings and sales beat estimates. The company lowers its guidance for 2022 CDMO services revenues and adjusted net income.

Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More

by Zacks Equity Research

Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.

Endo (ENDP) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Endo's (ENDP) fourth-quarter earnings might have gained from higher sales of Xiaflex.

Viatris (VTRS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Viatris' (VTRS) Q4 earnings might have gained from the solid performance of Lipitor, Influvac, Viagra and EpiPen.

What's in the Cards for Bausch Health (BHC) Q4 Earnings?

by Zacks Equity Research

An update on the IPO of Bausch+Lomb and regular top-line and bottom-line numbers will grab investors' attention when BHC reports Q4 results.

Emergent (EBS) Begins Dosing in Study on Influenza Vaccine

by Zacks Equity Research

Emergent (EBS) initiates a phase I study evaluating EBS-UFV-001, the company's investigational universal influenza vaccine candidate.

Emergent (EBS) Q3 Earnings Miss, Contract Revenue View Down

by Zacks Equity Research

Emergent's (EBS) third-quarter 2021 earnings and sales miss estimates. The company tightens the revenue guidance on lower anticipated revenues from the CDMO segment. Stock down in after-market trading.

Emergent Biosolutions (EBS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -117.73% and -27.57%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Emergent Biosolutions (EBS) Q3 Earnings Expected to Decline

by Zacks Equity Research

Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Emergent (EBS) Inks COVID-19 Manufacturing Deal With Providence

by Zacks Equity Research

Emergent (EBS) is set to provide manufacturing services for doses of Providence Therapeutics' COVID-19 vaccine candidate as well as for its bulk drug substance.

New Strong Sell Stocks for August 2nd

by Zacks Equity Research

ATTO, BLDP, NTB, CCJ and EBS have been added to the Zacks Rank #5 (Strong Sell) List on August 2, 2021.

Emergent (EBS) Misses on Q2 Earnings, to Restart Bayview Unit

by Zacks Equity Research

Emergent's (EBS) second-quarter 2021 earnings miss estimates. Revenues also fail to meet expectations. Stock down.

Emergent Biosolutions (EBS) Lags Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -81.77% and -4.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Emergent Biosolutions (EBS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vaxart (VXRT) Enters an Agreement With Altesa for Antiviral

by Zacks Equity Research

Vaxart (VXRT) enters a licensing agreement with Altesa Biosciences, Inc., whereby the latter gets rights to develop, manufacture and commercialize vapendavir.

AstraZeneca (AZN) Gets Court Order to Supply COVID-19 Jabs in EU

by Zacks Equity Research

A court in Brussels orders AstraZeneca (AZN) to supply 80 million doses of its COVID-19 vaccine to Europe by Sep 27, 2021. The European Commission had requested for 300 million doses by end of September.

J&J (JNJ) Gets FDA Nod for 10M COVID Vaccines, Discards Many

by Zacks Equity Research

J&J (JNJ) gets authorization for two batches of COVID-19 vaccine doses manufactured at Baltimore facility but the FDA discards several others. Europe and Canada stop the rollout of some batches of the vaccine.

Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?

by Zacks Equity Research

Sector ETF report for SBIO